 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12» |
- | gusacitinib (ASN002) / Formation Bio
New P1 trial: A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus (clinicaltrials.gov) - Feb 2, 2024
P1, N=60, Not yet recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- | sprifermin (AS-902330) / TrialSpark
Journal: Computer-assisted stabilization of fibroblast growth factor FGF-18. (Pubmed Central) - Nov 5, 2023
However, recent phase 2 clinical trial results of sprifermin (recombinant FGF18) indicate insufficient efficacy...Moreover, the FGF18-E4 maintained mitogenic activity after 1-week incubation at 37
- || ASN008 / TrialSpark
Enrollment closed: A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Oct 16, 2023
P2, N=120, Active, not recruiting, Sponsor: TrialSpark
However, recent phase 2 clinical trial results of sprifermin (recombinant FGF18) indicate insufficient efficacy...Moreover, the FGF18-E4 maintained mitogenic activity after 1-week incubation at 37 Recruiting --> Active, not recruiting
- sprifermin (AS-902330) / TrialSpark
Clinical and Imaging Characteristics of Individuals Who Underwent Knee Replacement During Years 3 to 5 in the FORWARD Study: A Post Hoc Analysis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2953;
P1, P2
Recruiting --> Active, not recruiting Pts treated with IA sprifermin 100
- sprifermin (AS-902330) / TrialSpark
Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study (Room 6F/6C; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1696;
Pts treated with IA sprifermin 100 These post hoc results support that sprifermin may prevent symptomatic progression of KOA, with benefits seen in both ITT and SAR populations for the sprifermin 100
- sprifermin (AS-902330) / TrialSpark
Impact of Sprifermin on Denuded Areas of Subchondral Bone (dABs): A Post Hoc Analysis of the FORWARD Study (Room 24A-C; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1628;
Sprifermin treatment, particularly at the highest dose, appears to slow the increase (worsening) of dAB compared to PBO, especially in the medial compartment. Further evaluation of these findings and the relationship of dAB with symptomatic outcomes is warranted, including in prospective clinical trials.
- || Review, Journal: [[Translated article]]Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives. (Pubmed Central) - Sep 7, 2023
We review a number of JAK inhibitors that have been recently approved for use in atopic dermatitis, such as baricitinib, upadacitinib, and abrocitinib, as well as others that are currently in the pipeline or under development, such as gusacitinib, delgocitinib, ruxolitinib, brepocitinib, tofacitinib, and cerdulatinib. The use of JAK inhibitors to block the signaling of numerous cytokines with a critical role in the pathogenesis of atopic dermatitis has revolutionized the treatment of this pathogenically complex, phenotypically heterogeneous skin disease.
- || Review, Journal: Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives. (Pubmed Central) - Sep 7, 2023
We review a number of JAK inhibitors that have been recently approved for use in atopic dermatitis, such as baricitinib, upadacitinib, and abrocitinib, as well as others that are currently in the pipeline or under development, such as gusacitinib, delgocitinib, ruxolitinib, brepocitinib, tofacitinib, and cerdulatinib. The use of JAK inhibitors to block the signaling of numerous cytokines with a critical role in the pathogenesis of atopic dermatitis has revolutionized the treatment of this pathogenically complex, phenotypically heterogeneous skin disease.
- || Review, Journal: A Review of Existing and New Treatments for the Management of Hand Eczema. (Pubmed Central) - Jul 27, 2023
Two major classes of drugs emerging for the treatment of hand eczema include IL-4/IL-13 inhibitors and JAK inhibitors. With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician's management toolbox for patients with hand eczema.
- || gusacitinib (ASN002) / TrialSpark
P2 data, Journal: Oral SYK/JAK Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study. (Pubmed Central) - Jul 18, 2023
With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician's management toolbox for patients with hand eczema. Gusacitinib showed rapid improvement in CHE patients and was well tolerated warranting further investigations.
- || Review, Journal: Updated Review on Treatment of Atopic Dermatitis. (Pubmed Central) - Jun 19, 2023
We begin with topical treatments such as corticosteroids and calcineurin inhibitors and subsequently address the latest systemic treatments, such as Janus kinase inhibitors (upadacitinib, baricitinib, abrocitinib, gusacitinib) and interleukin (IL) inhibitors, which have proven efficacious in AD, namely, dupilumab (IL-4 and IL-13), tralokinumab (IL-13), lebrikizumab (IL-13), and nemolizumab (IL-31). Given the large number of drugs available, we summarize the pivotal clinical trials for each drug, evaluate recent real-world experience in terms of safety and efficacy for purposes of compilation, and provide evidence to guide the optimal choice of therapy.
- | ASN008 / TrialSpark
New P2 trial: A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - May 23, 2023
P2, N=120, Recruiting, Sponsor: TrialSpark
- sprifermin (AS-902330) / TrialSpark
Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post-hoc Analysis of the FORWARD Randomized Trial (Poster View) - Apr 2, 2023 - Abstract #EULAR2023EULAR_2533;
As differences between the sprifermin- and PBO-treated groups were detectable in a 3-year time frame, time to symptomatic progression of KOA could be a meaningful endpoint for an investigational DMOAD trial. Symptomatic and structural benefits of sprifermin need to be confirmed in the planned Phase 2b SPRING study.
- || sprifermin (AS-902330) / TrialSpark
Preclinical, Review, Journal: Preclinical Use of FGF-18 Augmentation for Improving Cartilage Healing Following Surgical Repair: A Systematic Review. (Pubmed Central) - Mar 9, 2023
Symptomatic and structural benefits of sprifermin need to be confirmed in the planned Phase 2b SPRING study. This systematic review provides evidence that rhFGF-18 significantly improves cartilage healing at 6 months postoperatively following microfracture or osteochondral defect repair in preclinical randomized controlled trials.
- || sprifermin (AS-902330) / TrialSpark
Clinical, Review, Journal: How Effective Are Non-Operative Intra-Articular Treatments for Bone Marrow Lesions in Knee Osteoarthritis in Adults? A Systematic Review of Controlled Clinical Trials. (Pubmed Central) - Dec 24, 2022
Two studies of sprifermin, one of autologous protein solution (APS) and one of high-dose TissueGene-C, reported a positive effect on OA-BMLs under 1-year follow-up...Overall, we found mixed evidence on the efficacy of intra-articular therapy for improving OA-BMLs in KOA. Additional studies with long-term follow-up are needed to confirm the effect of various intra-articular therapies on OA-BMLs in KOA.
- | sprifermin (AS-902330) / TrialSpark
Preclinical, Journal: The recombinant human fibroblast growth factor-18 (sprifermin) Improves Tendon-to-Bone Healing by promoting chondrogenesis In a Rat Rotator Cuff Repair Model. (Pubmed Central) - Jul 28, 2022
rhFGF-18/SA improved tendon-to-bone healing in the rats by promoting regeneration of the fibrocartilage enthesis. rhFGF-18 (sprifermin) may be beneficial in improving tendon-to-bone healing after rotator cuff repair.
- || sprifermin (AS-902330) / TrialSpark
Clinical, Journal: Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. (Pubmed Central) - Jun 28, 2022
P2
In the longest DMOAD trial reported to date, sprifermin maintained long-term structural modification of articular cartilage over 3.5 years post-treatment. Potential translation to clinical benefit was observed in the SAR.
- | sprifermin (AS-902330) / TrialSpark
Preclinical, Journal: Tc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model. (Pubmed Central) - May 19, 2022
Under sprifermin, Tc-NTP 15-5 uptake in pathological knees was significantly increased compared to controls, at 7-, 12- and 24-weeks, and consistent with proteoglycan increase measured 5 weeks post-surgery, as a sign of cartilage matrix remodelling. Our work highlights the potential of Tc-NTP 15-5 as an imaging-based companion to monitor cartilage remodelling in OA and DMOAD response.
- Clinical efficacy and safety of monoclonal antibody against Nerve Growth Factor and Fibroblast Growth Factor-18 therapy of osteoarthritis (Poster View 8) - May 6, 2022 - Abstract #EULAR2022EULAR_2523;
Based on the results of current research findings, NGF inhibitors relieved pain and enhance joint function and may be considered as the most effective for functional improvement. FGF-18 decrease the cartilage loss and may improve cartilage thickness.
- | sprifermin (AS-902330) / TrialSpark
Journal: Recombinant Fibroblast Growth Factor-18 (Sprifermin), Enhances Microfracture Induced Cartilage Healing. (Pubmed Central) - Apr 19, 2022
We detected a significant improvement in lameness scores, arthroscopic evaluations, radiography, and CT scans following sprifermin treatment when results from three dose-treatment groups were combined. Our results demonstrated, for the first time, an enhancement on microfracture outcomes following sprifermin treatment suggesting a cartilage regenerative role and a potential benefit of sprifermin treatment in early cartilage injuries.
- | sprifermin (AS-902330) / TrialSpark
Biomarker, Journal: Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: A pre-defined, exploratory biomarker analysis from the FORWARD study. (Pubmed Central) - Mar 11, 2022
Our results demonstrated, for the first time, an enhancement on microfracture outcomes following sprifermin treatment suggesting a cartilage regenerative role and a potential benefit of sprifermin treatment in early cartilage injuries. Patients with low serum PRO-C2 levels lost more cartilage thickness over time and grew more cartilage in response to sprifermin vs. a placebo when compared to patients with high PRO-C2 levels.
- || sprifermin (AS-902330) / EMD Serono
Review, Journal: Sprifermin: Effects on Cartilage Homeostasis and Therapeutic Prospects in Cartilage-Related Diseases. (Pubmed Central) - Jan 4, 2022
Sprifermin (recombinant human FGF18, rhFGF18) is an effective DMOAD, which can not only promote the proliferation of articular chondrocyte and the synthesis of extracellular matrix, increase the thickness of cartilage in a dose-dependent manner, but also inhibit the activity of proteolytic enzymes and remarkedly slow down the degeneration of cartilage. This paper reviews the unique advantages of Sprifermin in repairing cartilage injury and improving cartilage homeostasis, aiming to provide an important strategy for the effective prevention and treatment of cartilage injury-related diseases.
- | sprifermin (AS-902330) / EMD Serono
Journal: Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis. (Pubmed Central) - Sep 29, 2021
Current studies show good tolerability and no safety concerns. Well-designed phase 3 clinical trials are required to examine its effects on symptoms and cartilage loss in knee OA.
- || sprifermin (AS-902330) / EMD Serono
Clinical, P2 data, Retrospective data, Journal: Osteoarthritis and Cartilage, brief report Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study. (Pubmed Central) - Sep 24, 2021
Cartilage thickness assessed by automated segmentation provided a consistent dose response in structural modification compared with manual segmentation. This is the first time that two independent quantification methods of image analysis have reached the same conclusions in an interventional trial, strengthening the conclusions that sprifermin modifies structural progression in knee osteoarthritis.
- | sprifermin (AS-902330) / EMD Serono
Journal: The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. (Pubmed Central) - Sep 24, 2021
P2
Selection for low mJSW and moderate-to-high pain at baseline resulted in more rapid disease progression and demonstrated translation of structure modification (with maintained net benefit on total cartilage thickness) into symptomatic benefit. This subgroup may represent a target population for future trials.
- | sprifermin (AS-902330) / EMD Serono
Journal: Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over two years. (Pubmed Central) - Aug 4, 2021
Positive effects associated with sprifermin were observed for cartilage morphology changes, and BML improvement. There were no meaningful negative or positive effects associated with sprifermin in the other joint tissues examined.
- || sprifermin (AS-902330) / EMD Serono
Retrospective data, Review, Journal: Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis. (Pubmed Central) - Jun 22, 2021
The data from the included studies provide strong evidence to determine the effect of intra-articular sprifermin on joint structure in individuals with KOA and show no specific adverse effects. Nevertheless, intra-articular sprifermin did not likely have any positive effect on symptom alleviation.
- | sprifermin (AS-902330) / EMD Serono
Journal: Sprifermin benefits maintained at 5 years. (Pubmed Central) - Jun 3, 2021
Nevertheless, intra-articular sprifermin did not likely have any positive effect on symptom alleviation. No abstract available
- || sprifermin (AS-902330) / EMD Serono, lorecivivint (SM04690) / Samumed, Samil Pharma
Review, Journal: Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-β signalling pathways. (Pubmed Central) - May 6, 2021
Likewise, low levels of Wnt activity appear important to sustain chondrocyte viability but excessive activation is associated with progressive joint damage. Emerging clinical data suggest some potential for the use of sprifermin, a recombinant forms of fibroblast growth factor 18, a distant TGF-β superfamily member, and for lorecivivint, a Wnt pathway modulator.
- sprifermin (AS-902330) / EMD Serono
[VIRTUAL] Intra-articular sprifermin therapy reduces total knee replacements: accumulated evidence from translational and clinical data () - May 3, 2021 - Abstract #OARSI2021OARSI_347;
Studies published about the mode of action clearly demonstrate anabolic effects. Accumulated analysis of data available from preclinical experiments and clinical data was performed to investigate the effects of sprifermin on late stage OA tissues as well as the rate of total knee replacements (TKR) in late stage OA patients.
- sprifermin (AS-902330) / EMD Serono
[VIRTUAL] A low repair endotype is predictive for response to FGF-18 treatment: data from the phase II oa forward study () - May 3, 2021 - Abstract #OARSI2021OARSI_187;
With sprifermin, an increase in cartilage thickness in OA patients was recently demonstrated in the phase 2b trial FORWARD. PRO-C2, a biomarker of cartilage formation, was able 1) to stratify patients at baseline to identify superior responders, and 2) to demonstrate the effect of IA administrated sprifermin on cartilage turnover activity in synovial fluid (SF).
- | sprifermin (AS-902330) / EMD Serono
Journal: Sprifermin (recombinant human FGF18) is internalized through clathrin- and dynamin-independent pathways and degraded in primary chondrocytes. (Pubmed Central) - Mar 4, 2021
Finally, we show that sprifermin endocytosis is clathrin- and dynamin-independent and that receptor activation is not necessary for sprifermin's endocytosis. In this study, we link the role of endocytosis to the cell response and elucidate for the first time a de-sensitization phenomenon to a FGF.
- ||| sprifermin (AS-902330) / EMD Serono, lorecivivint (SM04690) / Samumed
I can easily see you bettering the current companies/thinking in the space, if desired: @Samumed_LLC - Lorecivivint (Wnt pathway) @Merck - Sprifermin (FGF-18) Histogen, Invossa etc. Various stem cell therapies EGFR signalling Maybe @bengoertzel and AGI can play a role? (Twitter) - Mar 1, 2021
- | sprifermin (AS-902330) / EMD Serono
Preclinical, Journal: Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo. (Pubmed Central) - Dec 17, 2020
At end of culture, the cartilage had sustained proteoglycan content and relative expression of ACAN < COL2A1 < SOX9 < COL1A1, indicating that functional chondrocytes remained in the explants. Sprifermin induces a temporal biphasic cartilage remodeling in human knee OA articular cartilage explants, with early-phase increased aggrecanase activity and late-phase increased type II collagen formation.
- sprifermin (AS-902330) / EMD Serono
[VIRTUAL] Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study (Feed 8) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2183;
Pain improvement vs PBO was sustained in a subgroup at risk of structural and symptomatic progression. This suggests potential disease modification with sprifermin, with delayed knee OA structural progression and translation of structural modification to clinical benefit.
- || sprifermin (AS-902330) / EMD Serono, Kineret (anakinra) / SOBI, Affibody
Review, Journal: Current Applications of Growth Factors for Knee Cartilage Repair and Osteoarthritis Treatment. (Pubmed Central) - Jul 28, 2020
These advances are in techniques for defect preparation and marrow stimulation, a common cartilage repair procedure used in combination with growth factor/cytokine augmentation. Multiple growth factor/cytokine modulation therapies are currently undergoing clinical trial investigation including Invossa (currently in phase III study), Kineret (currently in phase I study), and Sprifermin (currently in phase II study) for the treatment of symptomatic osteoarthritis.
- | sprifermin (AS-902330) / EMD Serono
Preclinical, Journal: Effects of sprifermin, IGF1, IGF2, BMP7 or CNP on bovine chondrocytes in monolayer and 3D culture. (Pubmed Central) - Jul 2, 2020
Regarding the cell phenotype, sprifermin appeared to be the only compound favoring the chondrocyte phenotype; it decreased type I collagen expression and had no hypertrophic effect. Together, these results confirm that sprifermin is a promising disease-modifying osteoarthritis drug.
- | sprifermin (AS-902330) / EMD Serono
Journal: Recombinant human FGF18 preserves depth-dependent mechanical inhomogeneity in articular cartilage. (Pubmed Central) - Jun 15, 2020
Sprifermin also affected ECM balance by maintaining the levels of extracellular collagen and suppressing matrix metalloproteinase production. These findings support the use of sprifermin as a medium additive for OCT allografts during in vitro storage and present a potential mechanism where sprifermin may impact a functional characteristic of articular cartilage in repair strategies.
- || ASN008 / TrialSpark
Trial completion: Study to Evaluate ASN008 Topical Gel (TG) (clinicaltrials.gov) - May 27, 2020
P1, N=24, Completed, Sponsor: Asana BioSciences
These findings support the use of sprifermin as a medium additive for OCT allografts during in vitro storage and present a potential mechanism where sprifermin may impact a functional characteristic of articular cartilage in repair strategies. Active, not recruiting --> Completed
- sprifermin (AS-902330) / EMD Serono
[VIRTUAL] SEPERATION OF HIGH AND LOW RESPONSE GROUPS IN OSTEOARTHRITIS USING SERUM CARTILAGE DEGRADATION AND FORMATION MARKERS – A 3 YEAR FOLLOW-UP ON THE FORWARD STUDY TESTING THE EFFICACY OF SPRIFERMIN (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_1565;
We noticed that low baseline PRO-C2 and CTX-II indicative for low metabolic activity of chondrocytes were associated with improved symptomatic outcome and slightly increased cartilage thickness compared to high metabolic activity. The parallelism between PRO-C2 and CTX-II point towards the existence of a low cartilage repair endotype and might reflect a subgroup of patients with higher sensitivity towards interventions - an effect that was maintained over three years.
- || sprifermin (AS-902330) / EMD Serono
Clinical, P2 data, Retrospective data, Clinical Trial,Phase II, Journal: Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial. (Pubmed Central) - May 17, 2020
P2
The parallelism between PRO-C2 and CTX-II point towards the existence of a low cartilage repair endotype and might reflect a subgroup of patients with higher sensitivity towards interventions - an effect that was maintained over three years. Sprifermin increases cartilage thickness, and substantially reduces cartilage loss, expanding FORWARD primary results.
- | sprifermin (AS-902330) / EMD Serono, methotrexate / Generic mfg., tanezumab (PF-4383119) / Eli Lilly, Pfizer
Review, Journal: Update Osteoarthritis (Pubmed Central) - Mar 19, 2020
New data are available on joint safety of the subcutaneously administered anti-nerve growth factor (NGF) molecule tanezumab. In OA treatment, pain, structure, and biomechanic impairment need to be addressed.
- sprifermin (AS-902330) / EMD Serono
[VIRTUAL] ASSESSMENT OF CARTILAGE DEGRADATION AND PROTECTIVE MARKERS IN SYNOVIAL FLUID FROM OSTEOARTHRITIS PATIENTS BEFORE AND AFTER CYCLES OF INTRA-ARTICULAR INJECTIONS WITH SPRIFERMIN (Maini) - Mar 4, 2020 - Abstract #EULAR2020EULAR_249;
Confirmatory of the preclinical investigations a biphasic response on cartilage turnover after injection with sprifermin was observed. Biochemical indications of cartilage formation and chondrocyte proliferation was only modulated in the sprifermin group, and cartilage degradation (ARGS) was temporal induced and reduced by sprifermin and placebo injections, respectively.
- |||| sprifermin (AS-902330) / TrialSpark
Trial completion: FORWARD: A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee (clinicaltrials.gov) - Nov 18, 2019
P2, N=549, Completed, Sponsor: EMD Serono
Biochemical indications of cartilage formation and chondrocyte proliferation was only modulated in the sprifermin group, and cartilage degradation (ARGS) was temporal induced and reduced by sprifermin and placebo injections, respectively. Active, not recruiting --> Completed
- |||| sprifermin (AS-902330) / EMD Serono
Update on new targets in #osteoarthritis, including targeting senescent synoviocyte to modulate SASP factors, ADAMTS-5, Wnt pathway, sprifermin. There is hope! (Twitter) - Nov 10, 2019
- || ASN008 / TrialSpark
Enrollment closed: Study to Evaluate ASN008 Topical Gel (TG) (clinicaltrials.gov) - Nov 3, 2019
P1, N=24, Active, not recruiting, Sponsor: Asana BioSciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | sprifermin (AS-902330) / EMD Serono
Clinical, Journal: Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. (Pubmed Central) - Oct 25, 2019
P2
Durability of response also was uncertain. ClinicalTrials.gov Identifier: NCT01919164.
- ||||| sprifermin (AS-902330) / EMD Serono
Clinical: Important structure modifying RCT in #osteoarthritis of sprifermin. Cartilage thickness improvement over placebo of uncertain clinical significance, with no accompanying symptom improvement at 2 years. https://t.co/fFACIRjLni (Twitter) - Oct 8, 2019
- |||| sprifermin (AS-902330) / EMD Serono
Clinical: Important structure modifying RCT in #osteoarthritis of sprifermin. Cartilage thickness improvement over placebo of uncertain clinical significance, with no accompanying symptom improvement at 2 years. https://t.co/wLXRJ2wi1G (Twitter) - Oct 8, 2019
- sprifermin (AS-902330) / EMD Serono
Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial (B206) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3809;
Despite substantial structural and symptomatic progression in the ‘ at risk ’ subgroup , structural improvement with sprifermin was maintained, and WOMAC score improvements vs PBO increased over time and were significant at Y ea r 3 . This supports further investigation of sprifermin as a potential disease-modifying osteoarthritis drug in a targeted population where structural improvement may translate into symptomatic benefit vs PBO with in a reasonable timeframe .